CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the safety of intravenous IMP administration in patients diagnosed with refractory and relapsed CD19 + B cell neoplasms.

Trial Details

NCT ID
NCT06593145
Phase
PHASE1
Sponsor
FamiCordTx
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • FCTX-CL19-1 (Tarcidomgen Kimleucel)
Locations (sample)
  • Warsaw, Ul. Banacha 1a, Poland|52.22977,21.01178
  • Gdansk, Ul. Smoluchowskiego 17, Poland|54.35227,18.64912

Key Eligibility Criteria

  • Adult patients 18-65 both inclusive;
  • Diagnosis of:
  • Refractory B-ALL (acute lymphocytic leukemia) - relapse after hematopoietic cell transplantation, second or more relapse in patients when transplan…
  • Large B-cell lymphoma including DLBCL NOS, lymphoma with high level of malignancy, follicular lymphoma transformed to DLBCL and primary mediastinal…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →